Retrospective evidence for a biological cost of vancomycin resistance determinants in the absence of glycopeptide selective pressures

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 3, 2011, Pages 608-610

  Johnsen, P J ^a   Townsend, J P ^b   Bohn T ^c   Simonsen, G S ^a,d,e   Sundsfjord, A ^a,d   Nielsen, K M ^a,c  

^a UNIVERSITY OF TROMSØ   (Norway)

^b YALE UNIVERSITY   (United States)

^c Research Park   (Norway)

^d UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^e NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Danish; Enterococcus faecium; GREF

Indexed keywords

AVOPARCIN; POLYPEPTIDE ANTIBIOTIC AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; DENMARK; ENTEROCOCCUS FAECIUM; GENETIC SELECTION; GLYCOPEPTIDE RESISTANT ENTEROCOCCUS FAECIUM; GLYCOPEPTIDE SUSCEPTIBLE ENTEROCOCCUS FAECIUM; HUMAN; NONHUMAN; POPULATION GENETIC PARAMETERS; POULTRY FARMING; PROMOTER REGION; RETROSPECTIVE STUDY;

ANIMALS; ANTI-BACTERIAL AGENTS; CARRIER STATE; DENMARK; ENTEROCOCCUS FAECIUM; GLYCOPEPTIDES; GRAM-POSITIVE BACTERIAL INFECTIONS; POULTRY; VANCOMYCIN RESISTANCE;

EID: 79951542262     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq512     Document Type: Article

References (14)

1. Seppala H, Klaukka T, Vuopio-Varkila J et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-6.
2. Enne VI, Livermore DM, Stephens P et al. Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet 2001; 357: 1325-8.
3. Andersson DI, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nature Rev Microbiol 2010; 8: 260-71.
4. Levin BR, Lipsitch M, Perrot V et al. The population genetics of antibiotic resistance. Clin Infect Dis 1997; 24 Suppl 1: S9-16.
5. Johnsen PJ, Townsend JP, Bohn T et al. Factors affecting the reversal of antimicrobial-drug resistance. Lancet Infect Dis 2009; 9: 357-64.
6. Wegener HC, Aarestrup FM, Jensen LB et al. Use of antimicrobial growth promoters in food animals and Enterococcus faecium resistance to therapeutic antimicrobial drugs in Europe. Emerg Infect Dis 1999; 5: 329-35.
7. Aarestrup FM, Seyfarth AM, Emborg HD et al. Effect of abolishment of the use of antimicrobial agents for growth promotion on occurrence of antimicrobial resistance in fecal enterococci from food animals in Denmark. Antimicrob Agents Chemother 2001; 45: 2054-9.
8. DANMAP. Use of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Bacteria From Food Animals, Foods, and Humans in Denmark. ISSN 1600-2032. http://www.danmap.org/ [all DANMAP reports 2001-08, p. 38 (2001), p. 31 (2002), p. 32 (2003), p. 44 (2004), p. 51 (2005), p. 47 (2006), p. 59 (2007) and p. 68 (2008)] (6 December 2010, date last accessed).
9. Hartl D, Clark AG. Principles of Population Genetics. Sunderland, MA: Sinauer Associates, Inc., 1997.
10. Nielsen KM, Townsend JP. Monitoring and modelling horizontal gene transfer. Nature Biotechnol 2004; 22: 1110-14.
11. Lenski RE, Rose MR, Simpson SC et al. Long-term experimental evolution in Escherichia coli. 1. Adaptation and divergence during 2,000 generations. Am Nat 1991; 138: 1315-41.
12. Foucault ML, Depardieu F, Courvalin P et al. Inducible expression eliminates the fitness cost of vancomycin resistance in enterococci. Proc Natl Acad Sci USA 2010; 107: 16964-9.
13. Willems RJ, Bonten MJ. Glycopeptide-resistant enterococci: deciphering virulence, resistance and epidemicity. Curr Opin Infect Dis 2007; 20: 384-90.
14. Sorum M, Johnsen PJ, Aasnes B et al. Prevalence, persistence, and molecular characterization of glycopeptide-resistant enterococci in Norwegian poultry and poultry farmers 3 to 8 years after the ban on avoparcin. Appl Environ Microbiol 2006; 72: 516-21.